16α-[18F]fluoro-17β-estradiol (FES; Cerianna GE HealthCare) was approved by the FDA for clinical use in 2020, and remains the only approved nuclear receptor imaging agent for patients with estrogen receptor positive (ER+) breast carcinoma. The gene discussed is ESR1; the disease is breast carcinoma.